<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> chemotherapy is often limited, since more than one molecule is usually involved with the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> pathogenesis </plain></SENT>
<SENT sid="1" pm="."><plain>A combination of therapeutic drugs would be a promising approach to overcome the complexity of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, a conjugate (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DA3</z:e>) of <z:chebi fb="0" ids="28834">deoxycholic acid</z:chebi> and low molecular weight polyethylenimine (<z:chebi fb="0" ids="53231">PEI</z:chebi> 1.8 kDa), which has a property that mimics that of cell penetrating <z:chebi fb="7" ids="16670">peptides</z:chebi> (CPPs), was used for simultaneous delivery of an anticancer drug and siRNA </plain></SENT>
<SENT sid="3" pm="."><plain>When complexed with siRNA, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DA3</z:e> showed significantly higher target gene silencing efficiency than <z:chebi fb="0" ids="53231">PEI</z:chebi> 25 kDa </plain></SENT>
<SENT sid="4" pm="."><plain>The gene silencing efficiency of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DA3</z:e> was maintained even in the presence of endocytosis inhibitors, suggesting that the polymeric carrier can mediate an endocytosis-independent macromolecular transduction similar to CPPs </plain></SENT>
<SENT sid="5" pm="."><plain>The capability of forming a micelle-like core-shell structure enables the conjugates to encapsulate and dissolve paclitaxel (PTX), a water-insoluble drug </plain></SENT>
<SENT sid="6" pm="."><plain>The drug-loaded cationic micelles can then interact with siRNA to form stable complexes (PTX/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DA3</z:e>/siRNA) </plain></SENT>
<SENT sid="7" pm="."><plain>The PTX/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DA3</z:e>/siRNA showed significantly enhanced inhibition of <z:e sem="disease" ids="C1516170" disease_type="Neoplastic Process" abbrv="">cancer cell growth</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>When administered into <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-bearing animals, the PTX/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DA3</z:e>/siRNA demonstrated significant suppression of <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e>, providing potential usefulness in clinical settings </plain></SENT>
</text></document>